FDA reviews peptide injections favored by RFK Jr. and wellness influencers
Outside advisers will weigh whether compounding pharmacies can make seven unapproved peptides as FDA scientists cite limited human data and contamination risks.
- On Wednesday, the Pharmacy Compounding Advisory Committee convened to determine if seven peptides, including TB-500 and BPC-157, should be added to the 503A Bulks List, permitting state-licensed compounding pharmacies to prepare the substances for patients with prescriptions.
- Popularized by social media influencers, demand for aesthetic and performance-enhancing peptides has surged. However, FDA staff reviewers warned last month that limited human clinical trial data exists to support safety or effectiveness for these substances' intended uses.
- Cell biologist Paul Knoepfler warned, "I see it as very risky," citing unproven science, while proponents argue regulated compounding access ensures better oversight than the currently booming unregulated grey market.
- More than 100 protesters rallied outside the FDA campus Wednesday demanding expanded access, while the Alliance for Pharmacy Compounding urged targeted safeguards ensuring quality standards and prescription requirements.
- Any recommendation from the panel remains advisory and not binding. Experts note the digital marketplace evolves faster than regulation, leaving the FDA facing difficult challenges in establishing frameworks that match online suppliers' agility while protecting public health.
139 Articles
139 Articles
The peptide industry's biggest power brokers are in Washington — and it could open up a multibillion-dollar market
Peptides are under scrutiny in an FDA meeting running July 23-24Olena Malik/Getty ImagesAn unconventional FDA panel is reviewing peptide safety, focusing on banned therapeutic peptides.The FDA raised concerns over peptide safety, citing immune reactions and a lack of evidence of efficacy.Better access to peptides could open up a multibillion-dollar market for telehealth companies.Nearly 2 years after Robert F. Kennedy Jr. vowed to end the FDA's …
MAHA Must Prepare for the Future of Medicine
This week, the Food and Drug Administration reviewed whether certain peptide therapies should be more widely available through compounding pharmacies. Some of the top names in longevity and health—including Brigham Buhler and Gary Brecka—arrived in Washington to weigh in on the latest Make America Healthy Again hot-button issue, raising questions about safety, innovation, and access....
FDA considers widening access to popular peptides
An FDA advisory committee began a two-day meeting to consider lifting a ban and widening access to seven popular peptides. They have seen a surge of support from wellness influencers and others, including Health Secretary Robert F. Kennedy Jr. Amna Nawaz discussed more with Dr. Dhruv Khullar, who wrote the New Yorker article, "Why Are People Injecting Themselves with Peptides?"
Coverage Details
Bias Distribution
- 64% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
